Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name 4-oxo-3-(3-oxo-1-phenylbutyl)chromen-2-olate
Drug ID BADD_D00005
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indications and Usage For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.
Marketing Status Discontinued; Prescription
ATC Code B01AA03
DrugBank ID DB00682
KEGG ID D00564
MeSH ID D014859
PubChem ID 23690541
TTD Drug ID D0E3OF
NDC Product Code 76282-329; 51407-348; 65162-769; 70934-587; 70934-911; 71610-448; 76282-334; 43353-030; 50090-3263; 51407-345; 51407-346; 65162-761; 65162-767; 70518-2395; 71610-462; 76282-335; 43353-029; 50090-2582; 50090-2586; 50090-5058; 70934-821; 76282-328; 43353-023; 50090-2617; 70518-2381; 70518-2382; 76282-333; 43353-028; 43353-054; 51407-341; 51407-343; 65162-766; 76282-330; 76282-331; 70518-2380; 71335-1824; 50090-2645; 51407-344; 51407-349; 65162-763; 70934-820; 71610-490; 76282-332; 50090-2654; 50090-2936; 51407-342; 65162-762; 65162-764; 70518-2383; 70518-2816; 76282-327; 43353-033; 51407-347; 70518-2394; 70518-2717; 71335-1595; 71335-1786; 71610-491; 43353-021; 43353-053; 50090-2613; 50090-2646; 65162-765; 65162-768; 71610-458; 71610-519
Synonyms Warfarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Apo-Warfarin | Aldocumar | Gen-Warfarin | Warfant | Coumadin | Marevan | Warfarin Potassium | Potassium, Warfarin | Warfarin Sodium | Sodium, Warfarin | Coumadine | Tedicumar
Chemical Information
Molecular Formula C19H15LiO4
CAS Registry Number 81-81-2
SMILES [Li+].CC(=O)CC(C1=CC=CC=C1)C2=C(OC3=CC=CC=C3C2=O)[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Coagulation time shortenedCytochrome P450 2C19P33261Not AvailableNot Available
HaemorrhageCytochrome P450 2C9P11712T19244Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin necrosis23.03.03.011--Not Available
Subdural haematoma24.07.04.005; 17.08.05.002; 12.01.10.003--Not Available
Swelling08.01.03.015--Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Ulcer08.03.06.001--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis24.05.02.001; 10.02.02.006--
Vomiting07.01.07.003--
Haemorrhage24.07.01.002--Not Available
Temperature intolerance08.01.09.022--Not Available
Blue toe syndrome24.01.02.004; 12.02.01.005--Not Available
Angiopathy24.03.02.007--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Infarction24.04.02.017--Not Available
Mediastinal disorder22.09.03.001--Not Available
Ill-defined disorder08.01.03.049--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Liver injury12.01.02.003; 09.01.07.022--Not Available
Traumatic liver injury09.01.08.010; 12.01.02.008--Not Available
The 3th Page    First    Pre   3    Total 3 Pages